Direct-to-consumer stem cell marketing and regulatory responses.
There is a large, poorly regulated international market of putative stem cell products, including transplants of processed autologous stem cells from various tissues, cell processing devices, cosmetics, and nutritional supplements. Despite the absence of rigorous scientific research in the form of randomized clinical trials to support the routine use of such products, the market appears to be growing and diversifying. Very few stem cell biologics have passed regulatory scrutiny, and authorities in many countries, including the United States, have begun to step up their enforcement activities to protect patients and the integrity of health care markets.
RIKEN Center for Developmental Biology, Kobe, Japan. sipp@cdb.riken.jp
Douglas
D
Sipp
D017277:Drug Approval; D006801:Humans; D040541:Marketing / Q000941:ethics* / Q000331:legislation & jurisprudence; D033581:Stem Cell Transplantation / Q000941:ethics* / Q000331:legislation & jurisprudence; D013234:Stem Cells / Q000166:cytology* / Q000502:physiology; D014182:Transplantation, Autologous; D014481:United States; D014486:United States Food and Drug Administration